STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Clinical trials for STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immunotherapy after surgery may keep lung cancer at bay
Disease control OngoingThis study tests whether adding the immunotherapy drug nivolumab after surgery and chemotherapy can help prevent non-small cell lung cancer from coming back. About 900 adults with stage IB to IIIA lung cancer who had their tumor completely removed are taking part. Nivolumab works…
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 10:16 UTC
-
Could a new drug boost lung cancer treatment?
Disease control OngoingThis study tests whether adding the drug veliparib to standard chemoradiation helps people with stage III non-small cell lung cancer that can't be surgically removed. It first finds the best dose, then compares the combination to standard treatment alone. About 53 adults particip…
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 10:06 UTC
-
New combo aims to outsmart Drug-Resistant lung cancer
Disease control OngoingThis early-phase trial tests a combination of two drugs, sapanisertib and osimertinib, in people with advanced EGFR-mutant non-small cell lung cancer whose cancer has worsened after previous treatment. The main goal is to find the safest dose and understand side effects. About 36…
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 09:35 UTC
-
Lung cancer pill after surgery shows promise in targeted trial
Disease control OngoingThis study tests whether taking erlotinib (a daily pill that blocks cancer growth signals) after surgery helps people with a specific type of lung cancer (EGFR-mutant) live longer compared to just watching and waiting. About 390 participants who had their lung cancer completely r…
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New cocktail for inoperable lung cancer shows promise in early trial
Disease control OngoingThis study tested a three-part treatment for people with stage III lung cancer that cannot be removed by surgery. The treatment combined standard chemotherapy (cisplatin and etoposide) with radiation, followed by two additional drugs (docetaxel and bevacizumab) to try to kill mor…
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced or inoperable solid tumors, including certain breast, lung, and pancreatic cancers. The goal is to see if the combo can shrink tumors or slow their growth by blocking enzymes that cancer …
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:04 UTC
-
Massive lung cancer study aims to match genes to treatments
Knowledge-focused OngoingThis study screens the genes of tumor samples from 8300 people with early-stage non-small cell lung cancer that has been or will be removed by surgery. The goal is to identify genetic changes that can help doctors choose the most effective targeted treatments for each patient. Pa…
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 26, 2026 09:35 UTC